[Progress of monoclonal antibody treatment for chronic rhinosinusitis with or without nasal polyps]

Chronic rhinosinusitis with or without nasal polyps mainly uses combination of medications represented by nasal glucocorticoids and functional sinus endoscopic surgery (FESS) and comprehensive treatment with antibiotics. The effect of oral antibiotics for CRS exacerbations on the microbial resistance rate in the population has not yet been fully assessed, but may be significant, and glucocorticoid-resistant CRS has also emerged. CRSwNP associated with complications of asthma is considered a more serious condition. It can have a major impact on the patient's quality of life. Therefore, there seems to be an urgent need for new strategies, including biologics to treat this common disease. Usually there is a TH2 bias in refractory CRS. Recently, studies of biologics have played a different role in severe airway disease, especially in Th2-biased CRSwNP, which opens up a new treatment approach compared with standard therapy. Biological therapy may help to improve patients with refractory CRSwNP clinical outcomes. Biological agents include monoclonal antibodies, cytokines, or receptors. Monoclonal antibodies currently available for the treatment of refractory CRS include omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, etc. This article describes the progress made in the treatment of chronic rhinosinusitis with or without nasal polyps with several monoclonal antibodies.